Guidelines on neuraminidase inhibitors in children are not supported by evidence

doi:10.1136/bmj.328.7433.227

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Mkael Symmonds, preregistration house officer (mkael@doctors.org.uk),
Nicholas J Matheson, preregistration house officer,
Anthony Harnden, university lecturer

Department of Surgery, Ayr Hospital, Ayr KA6 6DX
Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU
Department of Primary Health Care, Institute of Health Sciences, Oxford OX3 7LF

EDITOR—Guidelines from the National Institute for Clinical Excellence (NICE) on the use of neuraminidase inhibitors recommend oseltamivir for the treatment of at risk children with influenza-like illness of fewer than 48 hours' duration—for example, those with underlying chronic respiratory disease.1 The drug is not recommended for otherwise healthy children.

In our systematic review on the use of neuraminidase …